|Bid||3.1800 x 1100|
|Ask||3.2400 x 1000|
|Day's Range||3.1800 - 3.4199|
|52 Week Range||3.1800 - 12.6000|
|Beta (3Y Monthly)||2.05|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 13, 2019 - Mar 20, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||9.32|
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! In December 2018, Arbutus Biopharma Corporation (NASDAQ:ABUS) released its latest earnings announcement, which signalled...
- Clinical trial results expected for AB-506, a potent capsid inhibitor, and AB-729, a subcutaneously administered RNAi agent targeting HBsAg - Ongoing analyses of AB-452, a.
WARMINSTER, Pa., Feb. 28, 2019 -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that.
NEW YORK, Feb. 04, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
If you want to know who really controls Arbutus Biopharma Corporation (NASDAQ:ABUS), then you'll have to look at the makeup of its share registry. Generally speaking, as a company grows, Read More...
“Value has performed relatively poorly since the 2017 shift, but we believe challenges to the S&P 500’s dominance are mounting and resulting active opportunities away from the index are growing. At some point, this fault line will break, likely on the back of rising rates, and all investors will be reminded that the best time […]
NEW YORK, Dec. 11, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Looking for stocks with high upside potential? Just follow the big players within the hedge fund industry. Why should you do so? Let’s take a brief look at what statistics have to say about hedge funds’ stock picking abilities to illustrate. The Standard and Poor’s 500 Index returned approximately 5.7% in the 12 months ending October 26 […]
Mark Murray became the CEO of Arbutus Biopharma Corporation (NASDAQ:ABUS) in 2008. This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar Read More...
Arbutus Biopharma Corporation (ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that Dr. Frank Torti has been appointed as Chairman of the Company’s Board of Directors, effective November 26, 2018. “We are pleased to welcome Frank to our Board,” said Dr. Mark J Murray, President and CEO of Arbutus. For much of his career, Dr. Torti was a partner at New Enterprise Associates (NEA), a leading venture capital firm.
- AB-506, a second-generation capsid inhibitor, advanced to HBV patient portion of Phase 1a/1b clinical trial - ONPATTRO™ (patisiran) approved by the U.S. Food and Drug.
WARMINSTER, Pa., Oct. 31, 2018 -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that.
If you’re interested in Arbutus Biopharma Corporation (NASDAQ:ABUS), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could Read More...
Arbutus Biopharma (ABUS) provides updates on its HBV development programs. However, uncertainty and early to mid-stage of development remains a concern.
NEW YORK, NY / ACCESSWIRE / October 10, 2018 / U.S. equities finished mostly lower on Tuesday as interest rate increases and rising bond yields continued to put pressure on stocks. The Dow Jones Industrial ...
Today, Arbutus Biopharma (ABUS) stock is trading at $6.87, which is a 24.42% decline from its October 8 closing price of $9.09. Arbutus Biopharma’s closing price on October 8 represents ~111.0% growth from its 52-week low of $4.30 on December 15, 2017. On August 2, Arbutus Pharma hit its 52-week high of $12.60.